TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-77
SponsorRutgers, The State University of New Jersey

About this trial

Aim 1: Culturally adapt the TELESCOPE intervention for Hispanics. Using iterative qualitative feedback from a study-specific Community Advisory Board, focus groups, and interviews with community members, the investigators will culturally adapt the TELESCOPE intervention for Hispanics at high risk for lung cancer.

Aim 2: Assess the feasibility, acceptability, and implementation potential of the culturally adapted TELESCOPE intervention delivered by bilingual patient navigators for Hispanics. Hypothesis 1: The investigators expect a recruitment rate of ≥60%, ≥90% of Hispanic participants will complete the 1-week follow-up assessments, ≥80% of the key intervention components will be delivered with 80% fidelity by the patient navigators, and ≥90% of participants and clinicians will agree or completely agree that the intervention was feasible and acceptable.

Aim 3: Explore the impact of a culturally adapted TELESCOPE intervention delivered by bilingual patient navigators vs enhanced usual care (EUC) on the initial uptake of low-dose computed tomography (LDCT) and quality of the shared decision-making (SDM) process. Hypothesis 2: The investigators expect that an adapted TELESCOPE intervention will result in higher uptake of LDCT and higher SDM quality for lung cancer screening (LCS) compared to EUC.

Eligibility criteria

Qualifiers

Identify as Hispanic and/or Latino(a)

Able to read and speak in English or Spanish

Be 50 to 77 years of age

Be a current or former smoker

Disqualifiers

Do not speak English

Are not Hispanic or Latino(a)

Have a history of lung cancer

Had a CT scan in the past 12 months

Trial design

Treatments tested in this trial

  • TELESCOPE, Remote Decision Coaching with Navigation Intervention

Treatment groups

91 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Rutgers, The State University of New Jersey

Lead sponsor

New Jersey Commission on Cancer Research

Collaborator